We are live on ! Find out more
STML

Stemline Therapeutics, Inc.
STML

Delisted

STML was delisted on the 9th of June, 2020.

Back to rankings

66 hedge funds and large institutions have $63.3M invested in Stemline Therapeutics, Inc. in 2015 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 24 increasing their positions, 17 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 9

41% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 17

6% more funds holding

Funds holding: 62 → 66 (+4)

34% less capital invested

Capital invested by funds: $96.3M → $63.3M (-$33M)

Holders
66
Holders Change
+4
Holders Change %
+6.45%
% of All Funds
1.73%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
24
Reduced
17
Closed
9
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
+$418K

Top Buyers

Rank Fund Capital Flow
1
OAM
Oxford Asset Management
United Kingdom
+$1.44M
2
RA
Royce & Associates
New York
+$983K
3
EAM
Eventide Asset Management
Massachusetts
+$945K
4
Millennium Management
Millennium Management
New York
+$889K
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$882K

Top Sellers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
-$5.97M
2
GPP
Great Point Partners
Connecticut
-$4.2M
3
Goldman Sachs
Goldman Sachs
New York
-$3.65M
4
VM
VHCP Management
New York
-$2.56M
5
OPPM
Opus Point Partners Management
New York
-$662K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$12.4M +$882K +108,687 +6%
Franklin Resources
2
Franklin Resources
California
$10.2M +$412K +50,800 +3%
TCM
3
TimesSquare Capital Management
New York
$7.48M -$82K -10,100 -0.8%
EAM
4
Eventide Asset Management
Massachusetts
$5.37M +$945K +116,400 +16%
Vanguard Group
5
Vanguard Group
Pennsylvania
$2.97M +$96.7K +11,913 +3%
BFA
6
BlackRock Fund Advisors
California
$2.55M +$103K +12,719 +3%
BBA
7
Baker Bros. Advisors
New York
$2.1M – – –
VMI
8
VHCP Management II
New York
$1.99M +$2.56M +315,980 New
Millennium Management
9
Millennium Management
New York
$1.89M +$889K +109,603 +58%
State Street
10
State Street
Massachusetts
$1.32M +$145K +17,913 +9%
Mackenzie Financial
11
Mackenzie Financial
Ontario, Canada
$1.32M +$3.85K +475 +0.2%
BIT
12
BlackRock Institutional Trust
California
$1.22M +$141K +17,360 +10%
OAM
13
Oxford Asset Management
United Kingdom
$1.13M +$1.44M +177,638 New
Northern Trust
14
Northern Trust
Illinois
$1.07M -$1.53K -189 -0.1%
RA
15
Royce & Associates
New York
$1M +$983K +121,179 +319%
VM
16
VHCP Management
New York
$855K -$2.56M -315,980 -70%
Invesco
17
Invesco
Georgia
$816K -$31.2K -3,847 -3%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$662K +$941 +116 +0.1%
TI
19
Telemetry Investments
New York
$505K +$24.3K +3,000 +4%
PA
20
Perceptive Advisors
New York
$496K – – –
Renaissance Technologies
21
Renaissance Technologies
New York
$433K +$557K +68,600 New
TC
22
TFS Capital
Pennsylvania
$416K +$232K +28,585 +76%
TCIM
23
TIAA CREF Investment Management
New York
$383K -$117K -14,440 -19%
CLOS
24
Compagnie Lombard Odier SCmA
Switzerland
$382K – – –
BIM
25
BlackRock Investment Management
Delaware
$367K +$1.57K +193 +0.3%
1
2 3

STML Hedge Fund Activity: Q4 2015 in Review

66 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q4 2015, worth a combined $63.3M — down 34% from $96.3M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new STML positions and 9 closed out — a net gain of 4 holders — while 24 added to existing stakes and 17 trimmed.

The largest buyer was Oxford Asset Management, opening a new position worth an estimated $1.44M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $5.97M sold.

  • 66 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q4 2015, up from 62 in Q3 2015.
  • Funds reported $63.3M of Stemline Therapeutics, Inc. stock for Q4 2015, down 34% quarter-over-quarter.
  • 13 funds opened new Stemline Therapeutics, Inc. positions in Q4 2015 and 9 closed out, a net change of +4 holders.
  • The largest Stemline Therapeutics, Inc. buyer in Q4 2015 was Oxford Asset Management, an estimated $1.44M added.
  • The largest Stemline Therapeutics, Inc. seller in Q4 2015 was Farallon Capital Management, an estimated $5.97M sold.

Based on aggregated 13F filings for Q4 2015.